ILDS in the News 🌍 | 'What to Expect From the ILDS in 2025 and Beyond' ILDS President, Prof Henry W. Lim speaking to @derm_digest, sharing insights into recent and upcoming ILDS initiatives and how we are shaping the future of global skin health. 🎥 https://t.co/ij9QwSLD3d
Inhibition of Fatty Acid Binding Protein 5 (FABP5) demonstrates activity in psoriasis, according to research presented at the 34th Annual International Cannabinoid Research Society (ICRS) Symposium in Salamanca, Spain. https://t.co/QHPusgJhPa
Dr. Brett King recaps the inaugural 2024 RAVE conference in Chicago, sharing breakthroughs from the event that focused on revolutionizing the treatment of alopecia areata, vitiligo, and eczema. Gain insights from a leader in dermatology. https://t.co/L4MPUwaQX9
Limiting the use of oral corticosteroid treatment to 90 days or less may limit adverse effects in patients with #atopicdermatitis (AD).
This is the main takeaway from a new nested case-control study in @JAMANetworkOpen. https://t.co/VhSbXKvUw0
📰 HUGEL, Benev Skincare Partner to Bring New Toxin to U.S.
📰 FDA, EMA Accept BLA for New #Stelara Biosimilar
📰 FDA Extends Dosage Allowance for #revyve™ Wound Gel
https://t.co/rLwIQ61bVZ
The US FDA has approved the sNDA for roflumilast cream 0.15% (Zoryve, @ArcutisBio), a next-generation topical phosphodiesterase 4 (PDE4) inhibitor, for the treatment of mild to moderate #atopicdermatitis in adults and pediatrics six years of age and older. https://t.co/KFaLmYHsRu
Douglas DiRuggiero, PA-C, talks to Dr. Chovatiya about why & how to encourage non-segmental vitiligo patients to stick with daily application of ruxolitinib cream 1.5% (Opzelura, Incyte). They also discuss how it repigments multiple body parts in vitiligo. https://t.co/ux3hVAOgOd
Avrom Caplan, MD, an Assistant Professor in the Dept of #Dermatology at @nyugrossman, shares details on the first reported U.S. case of a sexually transmitted form of #ringworm caused by Trichophyton mentagrophytes type VII (TMVII). https://t.co/Pkaet6TDXg
Join #IPC Chief Medical Officer Peter van de Kerkhof in an interview with @derm_digest, where he discusses the new consensus statement that IPC recently released on the definition and diagnostic criteria for generalized pustular psoriasis (#GPP).
https://t.co/ClX75GOvcj
TDD asked key thought leaders and editorial advisory board members to take out their crystal balls and weigh in on what’s to come in 2024 and beyond. #dermatology#dermatologist https://t.co/JWFC61FpyJ
@onepeloton@onepeloton this is the third time I am getting this message -- I've spoken to support team ad nauseam. This shouldn't be so hard. Do Better.